3-异丁基-1-甲基黄嘌呤
中文名称 | 3-异丁基-1-甲基黄嘌呤 |
---|---|
中文同义词 | 3-异丁基-1-甲基-2,6(1H,3H)-嘌呤二酮;3-异丁基-1-甲基黄嘌呤(IBMX),99%;3-ISOBUTYL-1-METHYLXANTHINE 3-异丁基-1-甲基黄嘌呤 IBMX;3-异丁基-1-甲基黄嘌呤(IBMX、1-甲基-3-异丁基黄嘌呤、3,7-二氢-3-异丁基-1-甲基-1H-嘌呤-2,6-二酮);3-异丁基-1-甲基-1H-嘌呤-2,6(3H,9H)-二酮;3-异丁基-1-甲基-3,9-二氢-1H-嘌呤-2,6-二酮;3-异丁基-1-甲基黄嘌呤(IBMX);3-异丁基-1-甲基化黄嘌呤 |
英文名称 | 3-ISOBUTYL-1-METHYLXANTHINE |
英文同义词 | 3,7-Dihydro-1-methyl-3-(2-methy;3-isobutyl-1-methyl-1H-purine-2,6(3H,9H)-dione;3-isobutyl-1-methyl-3,9-dihydro-1H-purine-2,6-dione;3-isobutyl-1-methyl-7H-purine-2,6-dione;3-isobutyl-1-methyl-7H-purine-2,6-quinone;3-Isobutyl-1-methyxanthine;3-isobutyl-1-methyl-7H-xanthine;3,7-Dihydro-1-methyl-3-(2-methylpropyl)-1H-purine-2,6-dione |
CAS号 | 28822-58-4 |
分子式 | C10H14N4O2 |
分子量 | 222.24 |
EINECS号 | 249-259-3 |
相关类别 | 小分子抑制剂;嘌呤;有机砌块;其他生化试剂;杂环砌块;其他化学试剂;科研试剂;生化试剂;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;标准品;其它;原料 |
Mol文件 | 28822-58-4.mol |
结构式 | ![]() |
3-异丁基-1-甲基黄嘌呤 性质
熔点 | 200-201 °C(lit.) |
---|---|
沸点 | 363.42°C (rough estimate) |
密度 | 1.2042 (rough estimate) |
折射率 | 1.6500 (estimate) |
储存条件 | -20°C |
溶解度 | DMSO:1 M,慢慢升温 |
形态 | 粉末 |
酸度系数(pKa) | 8.61±0.70(Predicted) |
颜色 | 米白色 |
BRN | 247859 |
稳定性 | 可在-20°C下的DMSO或乙醇溶液保存长达3个月。 |
InChIKey | APIXJSLKIYYUKG-UHFFFAOYSA-N |
CAS 数据库 | 28822-58-4(CAS DataBase Reference) |
Target | Value |
PDE3
() | 6.5 μM |
PDE4
() | 26.3 μM |
PDE5
() | 31.7 μM |
At 100 μM, KMUP-1 (a xanthine derivative) and IBMX are the most effective at inducing tracheal relaxation; the magnitude of the relaxation responses induced by KMUP-1 and IBMX are not significantly different. IBMX (100 μM) activates renal outer medullary K + (ROMK) channels (n=6, P<0.05) and prevents further channel activation by ANG II (n=6, P=NS) or cGMP. Of note is that pretreatment of cortical collecting duct (CCDs) isolated from high-K + (HK)-fed rats with IBMX (100 μM) for 20 min leads to a significant increase in tubular cAMP content to 1.43±0.35 pg/mm tubule length (n=14) compare with that measured in vehicle-treated controls (0.61±0.13 pg/mm tubule length, n=12, P<0.05).
IBMX, a non-selective PDE inhibitor significantly decreases the liver glycogen storage (mg/g, IBMX 22±1.5 P<0.001). In comparison with the control group, IBMX and mc5 significantly increase plasma glucose (blood glucose, mg/dl, control=141±3, IBMX=210±17 P<0.001 and mc5=191±13 P<0.01) while other test compounds (mc1, mc6, MCPIP and Win 47203) do not produce significant effect (control=141±3, mc1 160±7, mc6 175±9, MCPIP 179±8 and Win 47203 116±2 P>0.05) also mc2 does not change plasma glucose (control=141±3 and mc2=145±5). IBMX has the highest efficacy on increasing plasma glucose. Treatments with IBMX and Apocynin significantly decrease cold-induced elevation of right ventricular (RV) systolic pressure (23.5±1.8 and 24.2±0.6 mmHg, respectively) although they do not decrease RV pressure to the warm control levels. IBMX or Apocynin significantly reduces medial layer thickness (19.0±0.9, and 16.9±0.8 μm, respectively) and increases lumen diameter (62.7±4.2, and 59.5±4.3 μm, respectively) of small PAs in cold-exposed rats.
提供商 | 语言 |
---|---|
英文
|
|
英文
|
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | 22842 | 3-异丁基-1-甲基黄嘌呤 3-Isobutyl-1-methylxanthine, 99+% | 28822-58-4 | 1g | 2469元 |
2024/08/19 | 22842 | 3-异丁基-1-甲基黄嘌呤 3-Isobutyl-1-methylxanthine, 99+% | 28822-58-4 | 5g | 7969元 |